@ARTICLE{10.3389/fbioe.2020.00454, AUTHOR={Ahmad, Baseer and Hanif, Quratulain and Wei, Xubiao and Zhang, Lulu and Sabir, Naveed and Li, Zhongxuan and Cheng, Junhao and Khan, Shahzad Akbar and Basit, Abdul and Shahid, Muhammad and Rehman, Amin ur and Si, Dayong and Zhang, Rijun}, TITLE={In vitro Impact of Yeast Expressed Hybrid Peptide CATH-2TP5 as a Prophylactic Measure Toward Sepsis and Inflammation}, JOURNAL={Frontiers in Bioengineering and Biotechnology}, VOLUME={8}, YEAR={2020}, URL={https://www.frontiersin.org/articles/10.3389/fbioe.2020.00454}, DOI={10.3389/fbioe.2020.00454}, ISSN={2296-4185}, ABSTRACT={CATH-2TP5 is a linear cationic hybrid peptide, consequent from naturally occurring antimicrobial peptide (AMPs) Cathelicidin-2 (CATH-2) and Immunomodulatory peptide Thymopentin (TP5) having dynamic and potent anti-inflammatory activities without hemolytic effect. The biocompatible mechanism of CATH-2TP5 is favored to explore new methodologies in the direction of biomedical applications. In this retrospectively study, an antiendotoxin and anti-inflammatory hybrid peptide CATH-2TP5 was emulated into pPICZα-A and successfully expressed in Pichia pastoris (P. pastoris). The recombinant CATH-2TP5 was purified through the Ni-affinity column and reversed-phase HPLC. The purified CATH-2TP5 peptide exhibited robust anti-endotoxin activity and significantly (p < 0.05) neutralized the effect of lipopolysaccharide (LPS). Furthermore, the down-regulated effect of CATH-2TP was more pronounced (p < 0.05) on LPS-induced cytotoxic effects, nitric oxide secretion and pro-inflammatory cytokines (TNF-α, IL-6, and IL-1β) in murine RAW264.7 macrophages. As associated to control and parental peptide the number of apoptotic cells was also contracted with the treatment of CATH-2TP5. Thus, we concluded that CATH-2TP5 peptide may be used in various biomedical applications as a therapeutic drug.} }